This page ranks therapeutic concepts and ideas for neurodegenerative diseases based on mechanistic strength, development feasibility, and clinical potential.
| Rank | Idea | Target | Evidence | Feasibility |
|------|------|--------|----------|-------------|
| 1 | Triple amyloid-tau-inflammation | Multiple | High | Moderate |
| 2 | APOE4-specific immunotherapy | Amyloid | High | High |
| 3 | Tau vaccination with adjuvant | Tau | Moderate | High |
| 4 | Synaptic regeneration | Neural repair | Low | Low |
| 5 | Metabolic enhancement | Mitochondria | Moderate | Moderate |
| Rank |
Idea |
Target |
Evidence |
Feasibility |
| 1 |
GLP-1/GIP dual agonism |
Metabolism |
High |
High |
| 2 |
AMPA modulators |
Glutamate |
Moderate |
High |
| 3 |
PDE inhibitors |
cAMP |
Moderate |
Moderate |
| 4 |
5-HT6 antagonists |
Serotonin |
Moderate |
Moderate |
| Rank |
Idea |
Target |
Evidence |
Feasibility |
| 1 |
Alpha-synuclein aggregation inhibitor |
α-syn |
Moderate |
High |
| 2 |
GBA gene therapy augmentation |
Glucocerebrosidase |
Moderate |
Moderate |
| 3 |
LRRK2 kinase inhibitor |
LRRK2 |
High |
High |
| 4 |
Microglial modulation |
Neuroinflammation |
Moderate |
Moderate |
| Rank |
Idea |
Target |
Evidence |
Feasibility |
| 1 |
Long-acting dopamine agonist |
Dopamine |
High |
High |
| 2 |
Adenosine A2A antagonist |
adenosine |
Moderate |
High |
| 3 |
Levodopa-sparing combinations |
Multiple |
Moderate |
Moderate |
| Rank |
Idea |
Target |
Evidence |
Feasibility |
| 1 |
SOD1 gene silencing |
SOD1 |
High |
High |
| 2 |
C9orf72-targeted ASO |
C9orf72 |
High |
High |
| 3 |
Antisense for FUS |
FUS |
Moderate |
High |
| 4 |
Muscle strengtheners |
Muscle |
Moderate |
Moderate |
| 5 |
Metabolic modulators |
Energy |
Low |
Moderate |
| Rank |
Idea |
Innovation |
Risk |
| 1 |
Epigenetic modulation |
Very High |
High |
| 2 |
Microbiome-based therapy |
High |
Moderate |
| 3 |
Exosome therapeutics |
High |
Moderate |
| 4 |
Optogenetic approaches |
Very High |
Very High |
| 5 |
Gene editing (CRISPR) |
Very High |
High |
| Rank |
Drug |
Original Use |
Repurpose Score |
| 1 |
Metformin |
Diabetes |
85 |
| 2 |
Ibuprofen |
Pain/ inflammation |
80 |
| 3 |
Saracatinib |
Cancer |
75 |
| 4 |
Losartan |
Hypertension |
70 |
| 5 |
Valproic acid |
Epilepsy |
65 |
- GLP-1 agonists for AD: Existing diabetic drugs, strong evidence
- Tau immunotherapy: Multiple programs in clinic
- LRRK2 inhibitors: Genetic validation, first programs in clinic
- Alpha-synuclein aggregation inhibitors: Phase 2 data coming
- Gene therapies: Several IND-enabling
- Combination approaches: Rationale established
- Regenerative medicine: Stem cells, tissue engineering
- Gene editing: CRISPR applications
- Precision medicine: Mutation-specific approaches
| Idea |
Impact |
Timeline |
Unmet Need |
| Disease modification |
Very High |
5-10 years |
High |
| Early detection + treatment |
Very High |
3-5 years |
Very High |
| Symptom control |
Moderate |
1-3 years |
High |
| Prevention |
Very High |
10+ years |
Very High |
The following areas need additional content or pages:
- PSP (Progressive Supranuclear Palsy): No dedicated therapeutic ideas section
- CBS (Corticobasal Syndrome): No dedicated therapeutic ideas section
- MSA (Multiple System Atrophy): No dedicated therapeutic ideas section
- FTD (Frontotemporal Dementia): Limited therapeutic ideas coverage
- DLB (Dementia with Lewy Bodies): No dedicated therapeutic ideas section
- Combination therapies: Limited coverage of multi-target approaches
- Preventive strategies: Minimal content on prevention approaches
- Biomarker-driven therapies: Lacking integration with diagnostic content
- Gene therapy modalities: AAV, ASO, and CRISPR approaches need expansion
- Links to mechanism pages for each therapeutic approach
- Links to relevant clinical trial pages
- Links to target protein/gene pages